Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTissue DonorsTransplantation ChimeraStem CellsBone Marrow TransplantationGraft vs Leukemia EffectTreatment OutcomeMyeloablative AgonistsBusulfanRemission InductionVidarabineRecurrenceGraft vs Tumor EffectGraft SurvivalHistocompatibility TestingLymphocyte TransfusionImmunosuppressive AgentsLeukemia, Myeloid, AcuteRetrospective StudiesLeukemiaMultiple MyelomaSiblingsCord Blood Stem Cell TransplantationCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytomegalovirus InfectionsHematopoietic Stem CellsMinor Histocompatibility AntigensLiver TransplantationSalvage TherapyDisease-Free SurvivalWhole-Body IrradiationLymphocyte DepletionSurvival AnalysisAntilymphocyte SerumMyelodysplastic SyndromesVirus ActivationSurvival RateHistocompatibilityNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaMelphalanChimerismTime FactorsHepatic Veno-Occlusive DiseaseMesenchymal Stem Cell TransplantationCytomegalovirusCyclophosphamideHematopoietic Stem Cell MobilizationAntineoplastic Combined Chemotherapy ProtocolsT-LymphocytesLiving DonorsKidney TransplantationAcute DiseaseFollow-Up StudiesCell TransplantationPrimary MyelofibrosisAnemia, AplasticHLA AntigensEmbryonic Stem CellsHematologic DiseasesLeukemia, Myeloid, Accelerated PhasePrognosisBlood DonorsAntigens, CD34Transplantation ImmunologyAntibodies, NeoplasmImmunosuppressionRoseolovirus InfectionsCytarabineBenzamidesAdult Stem CellsLymphoproliferative DisordersImmunocompromised HostLeukemia, MyeloidFusion Proteins, bcr-ablAntineoplastic AgentsReceptors, Purinergic P2X5Graft RejectionHodgkin DiseasePyrimidinesNuclear FamilyGanciclovirGranulocyte Colony-Stimulating FactorInfectionPiperazinesLymphoma, Non-HodgkinHeart TransplantationFatal OutcomeCyclosporineImmunotherapy, AdoptiveLeukocyte TransfusionOpportunistic Infections